STOCK TITAN
  1. Home
  2. News
  3. NSPR

InspireMD, Inc. - NSPR STOCK NEWS

Welcome to our dedicated page for InspireMD news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on InspireMD stock.

InspireMD, Inc. (NASDAQ: NSPR), located at 800 Boylston Street, Suite 16041, Boston, Massachusetts, is a pioneering medical device company. It specializes in the development and commercialization of its proprietary MicroNet stent platform technology, which addresses complex vascular and coronary diseases. The company's flagship products include the CGuard Carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS).

The CGuard EPS, which integrates MicroNet technology with a self-expandable nitinol stent, is primarily used for carotid artery applications and is a significant revenue driver for the company. InspireMD operates globally, with key markets in Italy, Germany, Russia, among others.

In a recent move, InspireMD has focused on expanding its intellectual property portfolio to support its strategic direction. October 2023 saw the Centers for Medicare and Medicaid Services (CMS) expand coverage for carotid artery stenting, including asymptomatic and standard-risk patients. This development is expected to enhance the adoption of InspireMD's products.

Additionally, in the third quarter of 2023, InspireMD reported its financial results and ongoing projects. They are currently enrolling patients in a study to investigate the safety and feasibility of using CGuard EPS for treating acute ischemic stroke patients with tandem lesions. This study is expected to enroll 15 patients across three U.S. sites.

CEO Marvin Slosman emphasized the importance of this study in addressing carotid lesions in acute stroke settings, marking a crucial step in their long-term growth strategy. The company also continues its work on the Premarket Approval Application (PMA) for the C-GUARDIANS U.S. IDE trial, anticipating key milestones in 2024 and 2025.

InspireMD's common stock is listed on the Nasdaq under the ticker symbol NSPR. For more information, visit their website at www.inspiremd.com.

News

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

Rhea-AI Summary
InspireMD, Inc. (NSPR) appoints principal investigators for upcoming C-GUARDIANS II clinical trial of SwitchGuard™ Neuroprotection System, aiming to support Carotid Artery Stenting and Transcarotid Artery Revascularization procedures. The trial, led by renowned experts in vascular surgery, aims to advance the clearance of SwitchGuard™ NPS for improved patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
management clinical trial
-
News

InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework

Rhea-AI Summary
InspireMD, Inc. (NSPR) has received CE Mark recertification under the European Union's new Medical Device Regulation for its CGuard™ Embolic Prevention Carotid Stent System. The company is also making progress on the Premarket Approval Application for the C-GUARDIANS U.S. IDE trial and looks forward to primary endpoint results in mid-2024. InspireMD continues to work towards multiple value-creating milestones, including potential U.S. approval of the CGuard Prime EPS stent system in the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
none
-
News

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Rhea-AI Summary
InspireMD (Nasdaq: NSPR) appoints Pete Ligotti as Executive Vice President and General Manager of North America, bringing over 30 years of experience in medical technology. The company also grants Mr. Ligotti 138,460 shares of restricted stock and stock options to purchase 46,150 shares of common stock under NASDAQ listing rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
management
News

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

Rhea-AI Summary
InspireMD (Nasdaq: NSPR) announced the issuance of U.S. Patent No. 11,844,893, covering the SwitchGuard™ Neuroprotection System (NPS) for carotid artery disease treatment. The company aims to provide a complete solution set for carotid artery disease and stroke prevention, with a focus on expanding their product portfolio and adding intellectual property to support innovations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.5%
Tags
none
-
News

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

Rhea-AI Summary
InspireMD, developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, has entered into a strategic agreement with the Jacobs Institute at the State University of New York at Buffalo and Dr. Adnan Siddiqui to execute an Early Feasibility Study (EFS) evaluating the CGuard EPS carotid stent to treat severe carotid stenosis or occlusion, in conjunction with thrombectomy, in patients presenting with acute ischemic stroke and tandem lesions. The EFS is expected to enroll 15 patients across three U.S. trial sites and explore the safety and feasibility of using the CGuard EPS carotid stent, with its unique MicroNet™ mesh covering, to treat acute ischemic stroke patients with tandem lesions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
none
-
News

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
InspireMD, Inc. announced positive 30-day results from the C-GUARDIANS U.S. clinical trial, with a major adverse events rate of 0.95%. They also announced support for CMS' final decision to expand coverage of CAS to include more patients. Q3 2023 revenue was $1.56 million, up 9% from Q3 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
earnings
News

InspireMD to Participate in Upcoming November Investor Conferences

Rhea-AI Summary
InspireMD, Inc. announced that CEO Marvin Slosman will participate in three upcoming investor conferences in November. The conferences include Wolfe Research Healthcare Conference on November 15, Canaccord Genuity MedTech, Diagnostics, Digital Health & Services Forum on November 16, and Piper 35th Annual Healthcare Conference on November 29. The presentations will be available as a live webcast on the company's website with replays available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.41%
Tags
conferences
-
News

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

Rhea-AI Summary
InspireMD presents 30-day results from the C-GUARDIANS trial at the VIVA meeting. The trial evaluated the safety and efficacy of the CGuard Carotid Stent System in treating carotid artery stenosis. The primary endpoint showed a low major adverse event rate of 0.95% through 30 days post-procedure. InspireMD anticipates reporting primary endpoint results in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.21%
Tags
clinical trial
-
News

InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th

Rhea-AI Summary
InspireMD, Inc. (Nasdaq: NSPR) will report its third quarter 2023 financial results on November 6th, 2023. The company will host a conference call and webcast at 8:30 a.m. EST on the same day to review financial results and provide corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.07%
Tags
conferences earnings
News

InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients

Rhea-AI Summary
InspireMD supports CMS's expansion of coverage for carotid artery stenting, potentially increasing market size
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
none

FAQ

What is the current stock price of InspireMD (NSPR)?

The current stock price of InspireMD (NSPR) is $3 as of December 20, 2024.

What is the market cap of InspireMD (NSPR)?

The market cap of InspireMD (NSPR) is approximately 75.1M.

What does InspireMD, Inc. specialize in?

InspireMD specializes in the development and commercialization of proprietary MicroNet stent platform technology for vascular and coronary diseases.

What are the key products of InspireMD?

The key products are CGuard Carotid Embolic Prevention System (CGuard EPS) and MGuard Prime Embolic Protection System (MGuard Prime EPS).

Where is InspireMD headquartered?

InspireMD is headquartered at 800 Boylston Street, Suite 16041, Boston, Massachusetts, United States.

In which markets does InspireMD operate?

InspireMD operates in multiple countries, including Italy, Germany, and Russia.

What recent developments have been announced by InspireMD?

Recent developments include the expansion of CMS coverage for carotid artery stenting and ongoing studies for acute ischemic stroke treatment.

Who is the CEO of InspireMD?

The CEO of InspireMD is Marvin Slosman.

What are the financial results for InspireMD in the third quarter of 2023?

The detailed financial results for the third quarter of 2023 can be found in the company's report on Form 10-Q filed with the SEC.

What is the trading symbol for InspireMD?

InspireMD's common stock is quoted on Nasdaq under the ticker symbol NSPR.

What is the MicroNet technology?

MicroNet is a proprietary technology used in InspireMD's stent systems designed to provide superior embolic protection and enhance patient outcomes.

How can I get more information about InspireMD?

For more information, you can visit InspireMD's official website at www.inspiremd.com.

Stock NSPR logo
InspireMD, Inc.

Nasdaq:NSPR

NSPR Rankings

#4618 Ranked by Market Cap
N/A Ranked by Dividends

NSPR Stock Data

75.12M
19.52M
16.99%
40.85%
0.76%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
MIAMI